Evidence-Based Clinical Guidance

Modern weight-loss pills, guided by physician care.

A companion clinical guide for patients exploring oral prescription options beyond injectable GLP-1 therapy. Delivered with individualized dosing, tolerability monitoring, and comprehensive physician oversight.

Oral GLP-1 Receptor Agonists

Dual-Mechanism & Complementary Oral Therapies

Wegovy®

Oral GLP-1 Receptor Agonist

Wegovy® Pill

Once-daily oral semaglutide formulation engineered for effective gastric absorption and appetite modulation.

14% avg.

~33 lb average weight loss vs ~6 lb placebo in 64-week clinical investigation.

Foundayo™

Non-Peptide Oral GLP-1 RA

Foundayo™

Eli Lilly orforglipron—once-daily non-peptide small molecule taken without water or fasting restrictions.

11.1–14.7% avg.

Up to 24.9+ lb average loss in Phase 3 clinical trials without diabetes.

Qsymia®

Dual Action ER Combination

Qsymia®

Phentermine and topiramate extended-release—combines early satiety with neuro-mediated craving suppression.

13.7% top dose

Top dose trial result at 56 weeks; recommended dose average achieved 10.4% loss.

Neuro-Reward Modulator

Contrave®

Naltrexone HCl and bupropion HCl ER—acts synergistically on the hypothalamus and mesolimbic dopamine circuits.

3.7–8.1% avg.

Net weight reduction reported across three 56-week multicenter randomized trials.

Determine Which Medication Fits Your Biology

Every patient responds differently. Our physician-led team evaluates your cardiovascular profile, medical history, metabolic labs, tolerability, and insurance formulary to tailor your prescription plan.

Schedule Clinical Consultation • (214) 551-0308